No Data
No Data
Express News | Arrowhead Pharmaceuticals Initiates Expanded Access Program For Plozasiran
Arrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical Data
Arrowhead is committed to bringing new investigational medicines to patients with serious diseases as quickly and efficiently as possible.
Arrowhead Pharmaceuticals(ARWR.US) Director Buys US$82,990 in Common Stocks
$Arrowhead Pharmaceuticals(ARWR.US)$ Director Lu Hongbo purchased 3,000 shares of Common Stocks on Mar 18, 19, 20, 2024 at an average price of $27.66 for a total value of $82,990.Source: Announcement
Inventiva Phase 2 Study for MASH Drug Meets Primary Endpoint
Biotech Investors: Should You Buy, Hold, or Sell Moderna (MRNA) and Arrowhead Pharmaceuticals (ARWR)?
Madrigal Climbs Amid Hopes for New NASH Drug; B. Riley Upgrades
No Data